We have launched a new website for the association full of content and information about the generic, biosimilar and value-added medicines sector. Our members fulfil 85% of all NHS patient prescriptions and are integral to the safe and sustainable running of the UK's health systems.
medicinesuk.com
The latest episode of the Medicine Matters podcast is now available to listen and watch. Many thanks to Charles Joynson, founder of WaveData Ltd for his insight and expertise on pricing in the UK market. Please click on the link below.
#generics #biosimilars #NHS
bgma.podbean.com/e/medicine-m...
We were delighted to welcome @mhragovuk.bsky.social chief executive Lawrence Tallon to our Medicines UK members meeting today. Great discussion and engagement across a wide range of issues impacting the licencing and supply of generic and biosimilar medicines.
#generics #biosimilars #MHRA
Medicines UK chief executive Mark Samuels comments on the announcement today of the deal between the UK and US on pharmaceutical tariffs. Read the full statement below.
#generics #biosimilars
Listen to the latest episode of the Medicine Matters podcast featuring Adele Paterson, chief executive of International Health Partners. She talks about the vital role of the NGO in distributing essential medicines to where they are needed most.
bgma.podbean.com/e/medicine-m...
#generics
It was great to see our association leading a panel discussion at the CPC North event in Manchester at the end of last week on the topic of medicine shortages.
#generics #biosimilars #NHS
Next week, Medicines UK, alongside NHS England and the MHRA will be hosting a free one hour virtual webinar on streamlining the regulatory pathway for biosimilars in the UK. Full details below and how to reserve a place.
#biosimilars #NHS #mhra
Great discussions and insight shared at yesterday’s roundtable featuring medicines minister Dr Zubir Ahmed MP, who met with global leaders from some of the world’s leading off-patent companies. In the UK, generics and biosimilars fulfil 85% of NHS patient prescriptions.
#generics #biosimilars #NHS
The Chancellor will next week unveil her Autumn Statement to the nation. We have been examining the policy areas which can support our industry - which supplies 85% of the NHS' medicines - and help boost the broader UK economy. You can read our full submission at medicinesuk.com/view-news/20...
Our chief executive Mark Samuels today gave evidence to the House of Lords public services committee inquiry into medicines security.
parliamentlive.tv/event/index/...
Our reaction to the news that the National Institute for Health and Care Excellence (NICE) has recommended generic abiraterone for prostate cancer which will benefit thousands of patients by increasing access and saving the NHS millions of pounds.
Our chief executive Mark Samuels writes in the The Economic Times on the areas where further collaboration could occur between India and the UK in developing their free-trade agreement and why off-patent medicines are a natural place to start.
pharma.economictimes.indiatimes.com/news/pharma-...
Another episode has dropped of the Medicine Matters podcast from Medicines UK.
View here
podbean.com/eas/pb-kgyh9...
The latest episode of the Medicine Matters podcast is available to listen and download below. In this edition we discuss data and what patent expiries mean for NHS savings and increased patient access.
www.podbean.com/ew/pb-e759x-...
#generics #biologics #medicines
Creating a world class life sciences sector requires an ambitious, high performing regulator. Our chief executive Mark Samuels pens his thoughts on this critical topic for the think tank @ukandeu.bsky.social Read the full article below.
ukandeu.ac.uk/making-briti...
Our reaction below to the Department for Health Social Care and NHS England’s ongoing work and future plans to improve shortage management and strengthen medicines supply chain resilience.
You can read the full report at www.gov.uk/government/p...
#generics #biosimilars
Our latest monthly analysis of medicine supply issues has been published on our website. It shows that overall there is currently a decline in the total number of shortages. Figures are at at their lowest level for nearly three years.
www.medicinesuk.com/view-news/bg...
#generics #biosimilars
What does President Trump's letter to 17 pharmaceutical companies on most favoured nation pricing mean for the cost of medicines in the UK? Our chief executive Mark Samuels spoke to the BBC about this topic on BBC Radio 4. Listen to the link below from 32 mins.
www.bbc.co.uk/sounds/play/...
Only a few short weeks ago, Medicines UK held its first ever conference and we were delighted to welcome Minister of State at the Department of Health and Social Care Karin Smyth as the keynote speaker.
If you missed the event, see below for a taster.
vimeo.com/1105497497/1...
Our chief executive Mark Samuels was on the BBC's World Business Report this week discussing the impact of trade and tariffs. Listen to the interview on the link below.
www.bbc.co.uk/sounds/play/...
The Government's life sciences strategy is out today and we are delighted the recognition in there of the importance of the off-patent sector. See below the reaction from Medicines UK's chief executive Mark Samuels.
#generics #biosimilars
It's been a momentous week at Medicines UK with our inaugural conference. We welcomed health minister Karin Smyth MP who spoke about the importance of our sector to the NHS and outlined plans to make the UK the premier global location for biosimilar launches.
A brilliant day of insight, collaboration and partnership at the Medicines UK conference. The off-patent industry - which is responsible for supplying four out of five NHS medicines - came together to discuss the topics which matter most with colleagues across the supply chain and Government.
In an uncertain world, we must prioritise the resilience and security of medicines supply. Read the comments of our chief executive Mark Samuels in inews: inews.co.uk/news/health/...
The BGMA is now Medicines UK. Our new name reflects the scale of the contributions our members make to the overall medicines dispensed by the NHS.
Our new brand reinvigorates our mission to create a sustainable and cost-effective supply of generic and biosimilar medicines to UK patients.
We are proudly launching our new name and brand as our association becomes Medicines UK.
Our members supply the vast majority of prescription packs the NHS relies on.
Watch this short film from our chief executive Mark Samuels on why we have adopted a new name. Find out more: www.medicinesuk.com
